Tsukushi (TSK)

Overview

Tsukushi (TSK) is an extracellular matrix protein belonging to the small leucine-rich proteoglycan (SLRP) family, specifically categorized as a non-canonical class IV SLRP. As detailed in the document (page 2), Tsukushi plays an important role during early body patterning, neural plate formation, and interacts with major developmental signaling pathways, including Wnt, BMP, and Notch. Within the central nervous system (CNS), TSK is known to inhibit Wnt signaling and regulate processes such as retinal development.

Structurally, Tsukushi contains nine leucine-rich repeat (LRR) domains and is encoded by the TSKU gene, producing a glycosylated secreted protein. According to the document (page 3), Tsukushi expression increases in contexts such as estrogen-responsive breast cancer cells, vitamin K2-treated osteosarcoma cells, and hepatocytes exposed to estrogen or insulin, highlighting its involvement in extracellular matrix remodeling, collagen accumulation, bone metabolism, and metabolic regulation.

A TSK test is a blood test used to measure Tsukushi levels in serum or plasma (page 4). Its clinical relevance includes assessment of hyperthyroidism and monitoring metabolic and developmental processes (page 5).

Symptoms

Tsukushi itself is not a disease but a biomarker, so symptoms reflect clinical presentations that prompt doctors to evaluate TSK levels.

1. Symptoms Suggestive of Hyperthyroidism

The document lists TSK as a predictive factor for hyperthyroidism (page 5). Symptoms leading to testing may include:

1. Unexplained weight loss
2. Increased heart rate
3. Heat intolerance
4. Tremors or anxiety
5. Fatigue or sleep disturbances

These symptoms warrant a metabolic assessment, where TSK levels may support evaluation.

2. Symptoms of Metabolic Dysfunction

TSK is linked to whole-body energy expenditure and metabolic homeostasis (page 5). Indications prompting testing may include:

1. Persistent fatigue
2. Abnormal glucose handling
3. Weight fluctuations
4. Signs of metabolic syndrome

3. Symptoms Related to Fibrosis or ECM Remodeling

Clinical signs that could be associated with fibrosis in the liver, kidney, or lung may prompt clinicians to evaluate biomarkers like TSK (page 10). These include:

1. Shortness of breath
2. Edema
3. Abdominal discomfort
4. Reduced organ function

4. Symptoms of Tumor Progression

Tsukushi overexpression is noted in certain tumors (page 10). Patients may present with:

1. Unexplained masses
2. Weight loss
3. Localized pain
4. Organ-specific symptoms depending on tumor site

Causes

“Causes” in this context refer to biological reasons for elevated or altered Tsukushi levels, all drawn from the document.

1. Hormonal Regulation

Tsukushi RNA increases in response to estrogen (page 3). This indicates hormonally driven extracellular matrix remodeling or tumor behavior in affected tissues.

2. Bone and Collagen Metabolism

Tsukushi is upregulated alongside bone markers and contributes to vitamin K2–mediated collagen accumulation (page 3), explaining higher levels in bone-related metabolic changes.

3. Insulin and Metabolic Signaling

TSK transcription rises with insulin exposure in hepatocytes (page 3), tying it to metabolic conditions such as diabetes or insulin resistance.

4. Fibrotic Processes

TSK is elevated in liver, lung, and renal fibrosis (page 10). This increase reflects extracellular matrix remodeling during tissue injury and repair.

5. Tumor Growth and Metastasis

The document identifies TSK as overexpressed in cancers and associated with tumor progression (page 10).

Risk Factors

Risk factors involve clinical and biological situations where altered TSK levels are more likely.

1. Hyperthyroidism

Patients with thyroid overactivity demonstrate significantly higher TSK ranges (page 9).

2. Fibrotic Disorders

Conditions involving chronic organ damage—liver cirrhosis, pulmonary fibrosis, renal fibrosis—may raise TSK levels.

3. Cancers With ECM Remodeling

Tumors that rely on extracellular matrix modification may show elevated TSK, making cancer patients a higher-risk group (page 10).

4. Metabolic Conditions

TSK is associated with energy expenditure and metabolic regulation; abnormalities in these pathways can influence TSK levels (page 5).

5. Hormonal Influence

Estrogen-regulated tissues or hormone-dependent tumors may contribute to altered TSK expression (page 3).

6. Research Use Limitation

The document states that TSK testing is currently for research use only (page 11), limiting clinical application and requiring careful interpretation.

Prevention

Prevention here refers to avoiding testing errors, sample-related issues, and misinterpretation, since TSK levels themselves cannot be biologically prevented.

1. Follow Sample Collection Guidelines

1. Collect 3 mL blood in either plain or EDTA tubes (page 8).
2. Separate serum or plasma promptly.

2. Pre-Test Preparation

Page 7 recommends:

1. Fasting for 10–12 hours
2. Avoiding medications and supplements
3. Avoiding strenuous activity or stress before the test

These steps prevent inaccurate readings.

3. Use Validated Estimation Methods

Approved methods in the document include:

1. Sandwich ELISA
2. Direct ELISA
3. Immunohistochemistry (IHC)
4. Western blotting (page 6)

Correct method choice prevents analytical errors.

4. Consider Clinical Context

Because TSK is influenced by hormones, insulin, and fibrosis, clinicians should correlate lab values with symptoms and imaging findings.

5. Interpret Carefully Due to Research-Only Status

Since the test is not yet approved for routine diagnostics (page 11), cautious interpretation prevents misdiagnosis.

6. Monitor High-Risk Individuals

Patients with hyperthyroidism, fibrosis, or metabolic issues may benefit from periodic evaluation to track disease progression.